research P166 Real-world efficacy and tolerability of oral dutasteride combined with oral minoxidil for male androgenetic alopecia: a retrospective cohort study
The treatment effectively improved hair growth and was well tolerated in most men.
Search
for
Sort by
Research
480-510 / 1000+ results
research Drug-induced gynecomastia: A systematic review and meta-analysis of randomized clinical trials
Certain drugs, especially antiandrogens and spironolactone, significantly increase the risk of gynecomastia.
research Antiandrogens and Androgen Inhibitors
Antiandrogens and androgen inhibitors like spironolactone, finasteride, and dutasteride can treat hair loss and skin conditions, but they have risks and side effects, including potential harm to pregnant women and risks of cancer and heart issues. Herbal remedies also have antiandrogenic effects but lack safety validation.
research Acne
Hormonal treatments can help with acne, especially in women, by lowering androgen levels or blocking their effects.
research Issue information
Oophorectomy reduces ovarian cancer risk for women with BRCA mutations, finasteride lowers prostate cancer risk without raising death risk, and prophylactic mastectomy rates are rising.
research Androgens and Anti-androgen Therapy
Antiandrogen therapy, like cyproterone acetate, effectively treats acne, hirsutism, and hair loss.
research Topical Estrogen Therapy for Androgenetic Alopecia in Menopausal Females
Topical estrogen helps hair growth in menopausal women with no major side effects.
research 5α-Reductase inhibitors alter steroid metabolism and may contribute to insulin resistance, diabetes, metabolic syndrome and vascular disease: a medical hypothesis
Some hair loss and prostate drugs might increase the risk of diabetes and heart disease.
research Fluridil, a Rationally Designed Topical Agent for Androgenetic Alopecia: First Clinical Experience
Fluridil safely promotes hair growth in men with androgenetic alopecia.
research A cross‐sectional analysis of medications used by patients reporting alopecia areata on the FDA adverse events reporting system
Monoclonal antibodies are often linked to alopecia areata cases.
research Persistent Alopecic Patches Following Dutasteride Mesotherapy for Female Androgenetic Alopecia: A Case Series
Dutasteride mesotherapy for hair loss can cause lasting bald patches.
research Anti-Androgen Therapy in Female Adult Acne
Anti-androgens are safe and effective for treating moderate to severe adult female acne.
research A randomized phase II trial on the addition of dutasteride to combined androgen blockade therapy versus combined androgen blockade therapy alone in patients with advanced or metastatic salivary duct carcinoma – the DUCT study protocol
Adding dutasteride to therapy may improve treatment for advanced salivary duct cancer.
research Synthesis, antiproliferative, acute toxicity and assessment of antiandrogenic activities of some newly synthesized steroidal lactams
research Aromatase-independent testosterone conversion into estrogenic steroids is inhibited by a 5α-reductase inhibitor
Combining 5α-reductase and aromatase inhibitors may better reduce estrogen levels.
research Experimental Assessment of 3-meta-Pyridine-1,2,4-Oxadiazole Deoxycholic Acid Derivative as a Prototype of 5-α-Reductase Inhibitors in silico and in vivo Models
The new compound is a promising, less toxic alternative to finasteride for treating prostate issues.
research Evaluation of Androgen Receptor Expression and Its Association with Clinicopathological Features in Iraqi Women with Breast Cancer
Androgen receptor expression in Iraqi women with breast cancer has limited prognostic value.
research Baricitinib maintains regrowth of hair, eyebrows, and eyelashes over 3 years
Baricitinib helps keep hair, eyebrows, and eyelashes regrown for 3 years in most people with severe hair loss.
research Mesotherapy with bicalutamide: A new treatment for androgenetic alopecia
Bicalutamide mesotherapy may help with hair loss and seborrhea but needs more research.
research Safety and quality of life of CDK4/6 inhibitors therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: a multicenter cross-sectional survey in China
CDK4/6 inhibitors affect safety and quality of life differently, requiring careful use.
research Treatment of androgenic disorders with dexamethasone: Dose-response relationship for suppression of dehydroepiandrosterone sulfate
Lower doses of dexamethasone can safely reduce high DHEAS levels in women with androgenic disorders.
research Progress on clinical applications of chlormadinone acetate
Chlormadinone acetate is useful for birth control and treating various hormonal issues.
research A Prospective Randomized Trial Comparing Low Dose Flutamide, Finasteride, Ketoconazole, and Cyproterone Acetate-Estrogen Regimens in the Treatment of Hirsutism
All treatments reduce hair growth; low dose flutamide most effective with fewer side effects.
research Structural Characterization and Ligand Specific Protein Interactions of Androgen Receptor
SARM-induced changes in the androgen receptor are specific to each ligand and affect stability and protein interactions.
research Shortness of breath: an uncommon side-effect of cyproterone acetate in the treatment of androgenetic alopecia
Cyproterone acetate can cause rare shortness of breath in women.
research Incidence of alopecia from endocrine therapies in cancer
Hair loss is a common, often overlooked side effect of hormone treatments for breast and prostate cancer.
research Sexual, physical, and overall adverse effects in patients treated with 5α-reductase inhibitors: a systematic review and meta-analysis
Medications for hair loss and prostate issues can significantly increase the risk of sexual side effects and other negative symptoms.
research Dermatologic adverse events associated with afatinib: an oral ErbB family blocker
Afatinib often causes skin problems that need proactive management.
research 549 Temporary cell cycle arrest in human scalp hair follicles and their epithelial stem cells by ALRN-6924: A novel strategy to selectively protect p53-wildtype cells against paclitaxel-induced alopecia
ALRN-6924 may prevent hair loss caused by chemotherapy.
research LB822 Nutraceuticals known to promote hair growth do not interfere with the inhibitory action of tamoxifen in breast cancer cells
Hair growth supplements do not reduce the effectiveness of the breast cancer treatment tamoxifen.